Regeneron Pharmaceuticals (REGN)

Health Care · $81.8B market cap · SEC CIK 0000872589

Next reports on Oct 26, 2026, with analysts expecting $16.17 in earnings per share.

The case for REGN

• Generated $4.1B of free cash flow in FY2025, 28% of revenue.
• 28% of revenue drops through to net profit.
• Holds more cash ($3.1B) than long-term debt ($2.0B).
• Revenue growing 9.3% year over year.
• Has compounded revenue at 11.0% a year over five years.
• Gross margin of 86% absorbs cost shocks.

The case against

• Weakest against its peers: price/sales of 5.3× is higher than 62% of Health Care companies.
• Its weakest area is growth (59/100): revenue +9.3%, EPS +1.9%, +11.0% a year over five years.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

Key numbers

Five years of financials, as filed

Pulled from Regeneron Pharmaceuticals's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.

Share count is down 3.2% over 4 years. Buybacks have been shrinking the pie.

What Regeneron Pharmaceuticals says it does

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others: • competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its…

Risk factors REGN lists in its 10-K

• Intellectual Property and Market Exclusivity Risks
• Other Regulatory and Litigation Risks
• Risks Related to Our Reliance on or Transactions with Third Parties
• Other Risks Related to Our Business and Our Common Stock
• Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products
• We are substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent
• The commercial success of our products and product candidates is subject to significant competition
• If we or our collaborators are unable to continue to successfully commercialize our products, our business, prospects, operating results, and financial condition will be materially harmed
• Sales of our marketed products are dependent on the availability and extent of coverage and reimbursement and copay assistance from third-party payors and other third parties
• Implementation of a Medicare Drug Price Negotiation Program
• We rely on our collaborations with Bayer and Sanofi for commercializing some of our marketed products
• If our Antibody Collaboration with Sanofi is terminated, or Sanofi materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to
• develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, may be materially harmed
• Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices

Filings

Other Health Care companies